The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

第十届BPI WEEK 2025 生物医药创新周将于2025年2月19-20日在上海盛大举办！ 大会由商图信息主办，为期两天，特邀100+重量级权威讲者，分别领衔核酸、XDC与双多抗、小分子三大专场，集结1500余位 精英与会嘉宾齐聚，现场解疑答惑，碰撞出思想火花，带来精彩干货 ...

has announced the selection of FMC-220, a first-in-class covalent small-molecule activator of p53 Y220C designed to address potency and tolerability challenges of noncovalent approaches. In cancer ...

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance ...

p53 is often referred to as the “guardian of the genome” due to its critical role in maintaining genomic stability, but it can be altered in cancer with mutations such as Y220C. The Y220C ...

FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated ...